Yasunori Akashi

Dr. Yasunori Akashi

Urology, Nara hospital Kindai university, Ikoma, Nara, Japan
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YAYasunori Akashi
Yasunori Akashi
YYYutaka Yamamoto
Yutaka Yamamoto
MHMamoru Hashimoto
Mamoru Hashimoto
SAShogo Adomi
Shogo Adomi
KFKazutoshi Fujita
Kazutoshi Fujita
HUHirotsugu Uemura
Hirotsugu Uemura
Introduction: Immune checkpoint inhibitor (ICI) therapy has significantly improved the prognosis of some patients with advanced urothelial carcinoma (UC), but it does not provide high therapeutic efficacy in all patients. Therefore, identifying predictive biomarkers is crucial in determining which patients are candidates for ICI treatment. This study aimed to identify the predictors of ICI treatment response in patients with platinum-refractory advanced UC treated with pembrolizumab. Methods: Patients with platinum-refractory advanced UC who had received pembrolizumab at two hospitals in Japan were included. Univariate and multivariate analyses were performed to identify biomarkers for progression-free survival (PFS) and overall survival (OS). Results: Forty-one patients were evaluable for this analysis. Their median age was 75 years, and the vast majority of the patients were male (85.4%). The objective response rate was 29.3%, with a median overall survival (OS) of 17.8 months. On multivariate analysis, an Eastern Cooperative Oncology Group performance status (ECOG-PS) ≥ 2 (HR = 6.33, p = 0.03) and a baseline neutrophil-to-lymphocyte ratio (NLR) > 3 (HR = 2.79, p = 0.04) were significantly associated with poor OS. Antibiotic exposure did not have a significant impact on either PFS or OS. Conclusions: ECOG-PS ≥ 2 and baseline NLR > 3 were independent risk factors for OS in patients with platinum-refractory advanced UC treated with pembrolizumab. Antibiotic exposure was not a predictor of ICI treatment response.

12 February 2025 in Neurourology and Urodynamics
Verified
Journal Article
Open access
YAYasunori Akashi
Yasunori Akashi
KMKoji Miki
Koji Miki
KKKeisuke Kiba
Keisuke Kiba
YYYutaka Yamamoto
Yutaka Yamamoto
KFKazutoshi Fujita
Kazutoshi Fujita
AHAkihide Hirayama
Akihide Hirayama
Objective: To explore why older men awaken to urinate within 3 h after falling asleep, we examined diuretic and urine storage states associated with the first void after falling asleep.Methods: We enrolled 102 male patients, 50 years or older, hospitalized for prostate biopsy between November 2021 and September 2023. Patients were grouped based on their first undisturbed sleep period (FUSP): FUSP < 3 h or FUSP ≥ 3 h. A 24‐h frequency‐volume chart (FVC) was recorded. Urinary sodium, creatinine, and osmolality were measured from the first urine after sleep and upon waking. Free water clearance (FWC) and sodium clearance (SC) of the first urine after sleep were recorded. The urine storage state was calculated as the ratio of urine volume at first nocturnal voiding to the maximum voided volume (VV) according to 24‐h FVC.Results: Overall, 86 cases were analyzed. FWC was elevated in the first urine after sleep. It was significantly higher in the FUSP < 3 h group (p = 0.041). SC was elevated in the FUSP < 3 h group for both the first urine after sleep and the urine upon waking. The urine storage state tended to be lower in the FUSP < 3 h group (p = 0.057). Multivariate analysis revealed that FWC, SC, and the urine storage state independently associated with FUSP < 3 h.Conclusion: Decreased urine storage function, increased water diuresis, and increased sodium diuresis in the first urine after sleep are independent factors associated with FUSP < 3 h. Management of these factors may improve nocturia.Trial Registration: Institutional Review Board Certification Number: 679.

31 January 2025 in The Prostate
Verified
Journal Article
Open access
MNMitsuhisa Nishimoto
Mitsuhisa Nishimoto
MVMarco A. De Velasco
Marco A. De Velasco
YYYutaka Yamamoto
Yutaka Yamamoto
SFSaizo Fujimoto
Saizo Fujimoto
YAYasunori Akashi
Yasunori Akashi
KFKazutoshi Fujita
Kazutoshi Fujita
Background: The efficacy of abiraterone acetate varies among patients with high‐risk metastatic castration‐sensitive prostate cancer (mCSPC). Both androgen receptor (AR) and cytokeratin 18 (CK18) are markers of the luminal lineage of prostate cancer, and their expression levels have been suggested to affect the response to androgen deprivation therapy (ADT). This study aimed to predict the efficacy of abiraterone acetate in high‐risk mCSPC via immunohistochemical staining of biopsy specimens obtained at the time of prostate cancer diagnosis.Methods: We retrospectively analyzed 44 patients treated with abiraterone acetate in combination with ADT. AR and CK18 expression in prostate biopsy specimens were assessed using immunohistochemical staining.Results: AR and CK18 staining was not significantly associated with overall survival (OS). However, low AR staining was significantly associated with a shorter time to castration‐resistant prostate cancer (TTCRPC) compared with high AR staining (log‐rank test, p = 0.018). Similarly, low CK18 staining was significantly associated with a shorter TTCRPC compared with high CK18 staining (log‐rank test, p = 0.037).Conclusions: Immunohistochemical analysis of AR or CK18 expression in biopsy specimens may serve as a predictive biomarker of high‐risk mCSPC treated with abiraterone acetate.Trial Registration: None